Guardant Health to Report Fourth Quarter and Full Year 2025 Financial Results on February 19, 2026 Life Science Investing
BriaCell Patients' Images Show Regression and Resolution of Metastasized Tumors and Immune Activation Biotech Investing
Anchor Line Partners Supports Stoke Therapeutics' Growth by Securing a 98,500 Square-Foot Lease in Waltham, MA Life Science Investing
BriaCell Highlights Extended >18-47 Months Survival in Phase 2 Metastatic Breast Cancer Patients Biotech Investing
Guardant Health Receives FDA Approval for Guardant360® CDx as Companion Diagnostic for BRAFTOVI® Combination in Patients with BRAF V600E-Mutant Metastatic Colorectal Cancer Life Science Investing
Arcellx to Advance the Conversation on Its Platform and the Importance of Early CAR T Access for Patients with Multiple Myeloma During the 2026 Tandem Meetings Life Science Investing
PTC's Onshape Selected by Reditus Space to Accelerate Development of Reusable Orbital Reentry Capsule Life Science Investing
Guardant Health Announces Multi-Year Strategic Collaboration Agreement with Merck to Develop Companion Diagnostics and Commercialize New Cancer Therapies Using Guardant Infinity Smart Platform Life Science Investing
Telo Genomics Announces Non-Brokered Private Placement of Convertible Debentures for up to $1,200,000 Genetics Investing
